Investors

Jun 28, 2011

TSX Exchange Symbol: RVX

CALGARY, June 28, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announces today the presentation of additional new findings arising from analysis of data gathered in the Phase 2 ASSERT trial at the annual meeting of the European Atherosclerosis Society (EAS) in Gothenburg, Sweden.  The EAS is a prestigious meeting that brings together both clinicians and scientists to share new knowledge in the battle against atherosclerosis.  At the EAS, there were two presentations co-authored by prominent scientists from Resverlogix's Clinical Steering Committee.

Resverlogix's previous studies have demonstrated RVX-208 to be an orally active small molecules that raises Apolipoprotein A-I (apoA-I) production.  In the recently completed ASSERT trial, Resverlogix illustrated that RVX-208 enhanced biomarkers of reverse cholesterol transport (RCT) in keeping with its unique mechanism of action.  The on-going analysis of the ASSERT data yielded new findings that formed the substance of an EAS presentation entitled "Anti-Inflammatory Effects of a Novel Inducer of Apolipoprotein A-I Synthesis: Insights from the ASSERT Study" showing the potential role of RVX-208 in lowering hsCRP, a well-known biomarker of inflammation which is an important process in the pathogenesis of atherosclerosis.

Dr. Jan Johansson, Resverlogix's Senior Vice President of Medical Affairs, commented, "This observation is intriguing because it begins to shine a light on the actions of RVX-208 that may extend beyond the production of apoA-I."

A second EAS presentation entitled "Increasing Circulating Concentration of All HDL Particle Subclasses in Hyper-Responders to Apolipoprotein A-I Induction: Insights from the ASSERT Study" emphasized a unique mechanism by which RVX-208 augments RCT, a pathway for clearing cholesterol from the body.  Enhanced activity of this pathway is believed to not only stabilize, but possibly regress, atherosclerosis within coronary vessels.  Based on this information, Dr. Johansson stated, "We now know the characteristics of a large high-risk patient population in whom significant benefit may be gained from the actions of RVX-208."

Mr. Don McCaffrey, President & CEO of Resverlogix, continued, "Adding these new learnings to other observations from ASSERT underscores the rationale for ASSURE, a Phase 2b trial of RVX-208 in which atherosclerosis regression as determined by intravascular ultrasound (IVUS) and biomarkers of reverse cholesterol transport will be the measured over a 26 week period. We will continue to learn from these and additional findings from ASSERT so that we may apply this knowledge in the design of clinical trials which will target patient populations who have the greatest need."

About RVX-208
RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. Apolipoprotein A-I (apoA-I), the main component of high-density lipoprotein (HDL), represents the body's natural defense system against atherosclerosis by mediating reverse cholesterol transport (RCT), i.e. transport of peripheral cholesterol including that of the vessel wall to the liver for processing. To the Company's knowledge RVX-208 is the only orally active small molecule that selectively stimulates apoA-I production to increase levels of HDL. The use of this approach will enhance HDL functionality in mediating RCT, a pathway by which cholesterol that has accumulated in atheroma within the arterial wall can be transported to the liver for excretion, thus reducing or preventing atherosclerosis.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas PR program is the Company's primary focus which is to develop novel small molecules that enhance apoA-1 production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular diseases including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those risk factors discussed in the Company's Annual Information Form and January 31, 2011 MD&A which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.